1. Comparison of Intensive and Moderate Lipid Lowering With Statins After Acute Coronary Symptoms
- Author
-
Rene Belder, Daniel J. Rader, Carolyn H. McCabe, Marc A. Pfeffer, Steven V. Joyal, Jean L. Rouleau, Karen A. Hill, Eugene Braunwald, Allan M. Skene, and Christopher P. Cannon
- Subjects
medicine.medical_specialty ,Acute coronary syndrome ,Statin ,business.industry ,Unstable angina ,medicine.drug_class ,Atorvastatin ,Hazard ratio ,nutritional and metabolic diseases ,Obstetrics and Gynecology ,General Medicine ,medicine.disease ,Surgery ,Regimen ,Internal medicine ,medicine ,Cardiology ,lipids (amino acids, peptides, and proteins) ,Myocardial infarction ,business ,Pravastatin ,medicine.drug - Abstract
background Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear. methods We enrolled 4162 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and compared 40 mg of pravastatin daily (standard therapy) with 80 mg of atorvastatin daily (intensive therapy). The primary end point was a composite of death from any cause, myocardial infarction, documented unstable angina requiring rehospitalization, revascularization (performed at least 30 days after randomization), and stroke. The study was designed to establish the noninferiority of pravastatin as compared with atorvastatin with respect to the time to an end-point event. Follow-up lasted 18 to 36 months (mean, 24). results The median LDL cholesterol level achieved during treatment was 95 mg per deciliter (2.46 mmol per liter) in the standard-dose pravastatin group and 62 mg per deciliter (1.60 mmol per liter) in the high-dose atorvastatin group (P
- Published
- 2004
- Full Text
- View/download PDF